Project Grant R43HL170884
Award Date
9/5/23
Completion Date
8/31/24
Dollars Obligated
$275K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Irvington, NY 10533, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $590,283 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of Wisconsin - Madison. The grant aims to develop feedback-controlled closed-loop manufacturing processes to improve the robustness and reproducibility of differentiating human pluripotent stem cells (hPSCs) into cardiomyocytes (CMs). The key objectives are to: 1) identify 2D CM differentiation failure modes through integrated...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $568,264 to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company, to develop a scalable bioprocess for manufacturing human red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). The goal is to create a renewable source of designer RBCs with unique antigen profiles to help identify complex antibodies in...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a flexible bioelectronic microarchitecture that integrates a capillary-like delivery network and a tissue-like sensing network to improve cardiac tissue engineering. The $488,026 award supports the creation of a system that can efficiently deliver media and provide real-time physiological feedback to enhance the development of...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...
The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...
This National Science Foundation (NSF) Engineering Program (CFDA 47.041) Project Grant award of $600,000 to Dartmouth College aims to develop methodologies for efficiently manufacturing mature human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to accelerate drug development and cardiac disease modeling. The project will employ biochip design, machine learning, developmental biology, and tissue engineering approaches to enhance the structural and functional maturity of...
Khloris Biosciences, Inc. received a $3.46 million Project Grant from the National Institutes of Health National Heart, Lung and Blood Institute to develop and validate a collection of induced pluripotent stem cell-derived cardiomyocyte cell lines. Under the Cardiovascular Diseases Research program (CFDA 93.837), Khloris will establish 50 cell lines from healthy individuals and patients with common hereditary cardiac disorders such as hypertrophic cardiomyopathy, dilated cardiomyopathy, and long...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $279,750 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Northstar Genomics, LLC, a small disadvantaged business located in Eagan, Minnesota. The goal of this 2-year grant, awarded on May 25, 2025, is to significantly enhance the efficiency of generating human vasculature in a gene-edited pig for the purpose of providing an unlimited source of organs, such as hearts, for xenotransplantation. The...
This Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the underlying causes of why pluripotent-derived cardiomyocytes (PSC-CMs) fail to fully mature. The $2,249,307 award, provided to The Johns Hopkins University from September 1, 2024 to May 31, 2028, aims to leverage a comprehensive computational approach to identify a conserved gene regulatory network that underlies the...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...